PTC Therapeutics Stock To $84?
PTC Therapeutics (PTCT) stock has fallen by 12.3% in less than a month, from $73.57 on 15th Apr, 2026 to $64.55 now. What comes next? We believe there is a good chance of a stock rebound considering history of recovery post-dips and our current Attractive opinion of the stock. Read Buy or Sell PTC Therapeutics Stock to see how we arrive at this opinion.
Dip buying is a viable strategy for quality stocks that have a history of recovering from dips. As it turns out, PTCT stock passes basic quality checks. Historically, the median return for the 12-month period following sharp dips was 52%, with median peak return reaching 62%. We define sharp dip as stock going down 20% or more, in less than 30 day period.
Below, we get into details of historical dips and subsequent returns.
Historical Median Returns Post Dips
| Period | Past Median Return |
|---|---|
| 1M | 3.8% |
| 3M | 17.2% |
| 6M | 33.1% |
| 12M | 51.9% |
Historical Dip-Wise Details
PTCT had 23 events since 6/20/2013 where the dip threshold of -20% within 30 days was triggered
- 62% median peak return within 1 year of dip event
- 257 days is the median time to peak return after a dip event
- -25% median max drawdown within 1 year of dip event
| 30 Day Dip | PTCT Subsequent Performance | |||||||
|---|---|---|---|---|---|---|---|---|
| Date | PTCT | SPY | 1Y | Peak Return |
Max Drop |
# Days to Peak |
||
| Median | 52% | 62% | -25% | 257 | ||||
| 4082025 | -21% | -16% | 84% | 117% | -9% | 232 | ||
| 7032024 | -23% | 4% | 57% | 84% | -0% | 257 | ||
| 4182024 | -20% | -2% | 95% | 132% | 0% | 333 | ||
| 9152023 | -35% | -1% | 34% | 53% | -31% | 248 | ||
| 5302023 | -20% | 2% | -13% | 9% | -56% | 7 | ||
| 10282022 | -27% | 1% | -51% | 54% | -52% | 206 | ||
| 5112022 | -20% | -15% | 77% | 84% | -17% | 364 | ||
| 3012022 | -22% | -7% | 30% | 60% | -25% | 230 | ||
| 3242021 | -22% | -0% | -26% | 1% | -33% | 1 | ||
| 3162020 | -37% | -25% | 78% | 113% | 0% | 297 | ||
| 9252019 | -21% | 2% | 27% | 62% | -12% | 147 | ||
| 12172018 | -21% | -7% | 52% | 55% | -13% | 352 | ||
| 10222018 | -21% | -4% | 2% | 29% | -24% | 282 | ||
| 7312018 | -20% | 2% | 23% | 27% | -26% | 365 | ||
| 10242017 | -20% | 3% | 112% | 197% | -6% | 237 | ||
| 3022017 | -27% | 5% | 143% | 155% | -21% | 333 | ||
| 10242016 | -21% | -0% | 141% | 223% | -37% | 316 | ||
| 7282016 | -20% | 5% | 258% | 273% | -27% | 361 | ||
| 1112016 | -21% | -8% | -36% | 28% | -82% | 37 | ||
| 8132015 | -21% | 1% | -78% | 9% | -85% | 14 | ||
| 5052015 | -23% | -1% | -87% | 16% | -90% | 76 | ||
| 4032014 | -21% | 3% | 177% | 225% | -38% | 348 | ||
| 11062013 | -21% | 5% | 144% | 169% | -21% | 324 | ||
1Y Refers to 1 year or time since recent dip, whichever is smaller
PTC Therapeutics Passes Basic Financial Quality Checks
Revenue growth, profitability, cash flow, and balance sheet strength need to be evaluated to reduce the risk of a dip being the sign of a deteriorating business situation.
| Quality Metrics | Value | Quality Check |
|---|---|---|
| Revenue Growth (LTM) | 114.5% | Pass |
| Revenue Growth (3-Yr Avg) | 44.9% | Pass |
| Operating Cash Flow Margin (LTM) | 41.1% | Pass |
| Leverage (see below) | – | Pass |
| => Interest Coverage Ratio | 5.6 | |
| => Cash To Interest Expense Ratio | 12.8 |
Not sure if you can take a call on PTCT stock? Consider portfolio approach
The Best Investors Think In Portfolios
Stocks soar and sink – the key is staying invested. A balanced portfolio helps you ride market volatility, boosts gains, and reduces single stock risk.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.